J
Juan-Sebastian Saldivar
Researcher at City of Hope National Medical Center
Publications - 8
Citations - 327
Juan-Sebastian Saldivar is an academic researcher from City of Hope National Medical Center. The author has contributed to research in topics: Lung cancer & Germline. The author has an hindex of 5, co-authored 8 publications receiving 307 citations.
Papers
More filters
Journal ArticleDOI
Familial deletion within NLGN4 associated with autism and Tourette syndrome
TL;DR: A family with a wide variation in neuropsychiatric illness associated with a deletion of exons 4, 5, and 6 of NLGN4 is described, an autistic boy with a motor tic and his brother has Tourette syndrome and attention deficit hyperactivity disorder.
Journal ArticleDOI
Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking‐associated signature
Dongqing Gu,William A. Scaringe,Kai Li,Kai Li,Juan-Sebastian Saldivar,Kathleen A. Hill,Kathleen A. Hill,Zhenbin Chen,Kelly D. Gonzalez,Steve S. Sommer +9 more
TL;DR: Analysis of somatic EGFR mutations in non‐small‐cell lung cancer (NSCLC) and associated epidemiological and methodological data, including response to the tyrosine kinase inhibitors Gefitinib and Erlotinib finds that the mutation pattern does not differ significantly with respect to gender, age, or tumor histology.
Journal ArticleDOI
Noninvasive Prenatal Testing Using Cell‐Free Fetal DNA in Maternal Plasma
Nilesh Dharajiya,Tricia Zwiefelhofer,Xiaojun Guan,Vach Angkachatchai,Juan-Sebastian Saldivar +4 more
TL;DR: A brief overview of how noninvasive prenatal testing using next‐generation sequencing is performed is provided.
Journal ArticleDOI
p53 Testing for Li-Fraumeni and Li-Fraumeni-like syndromes.
TL;DR: This unit provides a protocol to perform germline mutation analysis of the p53 gene, designed for detecting germline alterations from DNA extracted from blood; however, with some additional optimization, it could also be used to detect somatic mutations inDNA extracted from tumors.
Journal ArticleDOI
The CAP-IASLC-AMP molecular testing guideline for the selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors.
Marc Ladanyi,Phil T. Cagle,Mary Beth Beasley,Dhananjay Chitale,Sanja Dacic,Giuseppe Giaccone,Robert B. Jenkins,David J. Kwiatkowski,Juan-Sebastian Saldivar,Jeremy A. Squire,Erik Thunnissen,Neal I. Lindeman +11 more
TL;DR: An effort to establish evidence-based recommendations for the molecular analysis of lung cancers required to guide EGFR- and ALK-directed therapies, addressing which patients and samples should be tested, and when and how testing should be performed is established.